Genetically engineered Bifidobacterium shows potential for oral delivery of cancer vaccine
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. In an exploratory Phase I clinical study, the vaccine was well tolerated and generated immunologic and clinical findings that warrant further investigation. The results a